Literature DB >> 28219660

Modelling and investigation of the CD4+ T cells - Macrophages paradox in melanoma immunotherapies.

Raluca Eftimie1, Haneen Hamam2.   

Abstract

It is generally accepted that tumour cells can be eliminated by M1 anti-tumour macrophages and CD8+ T cells. However, experimental results over the past 10-15 years have shown that B16 mouse melanoma cells can be eliminated by the CD4+ T cells alone (either Th1 or Th2 sub-types), in the absence of CD8+ T cells. In some studies, elimination of B16 melanoma was associated with a Th1 immune response (i.e., elimination occurred in the presence of cytokines produced by Th1 cells), while in other studies melanoma elimination was associated with a Th2 immune response (i.e., elimination occurred in the presence of cytokines produced by Th2 cells). Moreover, macrophages have been shown to be present inside the tumours, during both Th1 and Th2 immune responses. To investigate the possible biological mechanisms behind these apparently contradictory results, we develop a class of mathematical models for the dynamics of Th1 and Th2 cells, and M1 and M2 macrophages in the presence/absence of tumour cells. Using this mathematical model, we show that depending on the re-polarisation rates between M1 and M2 macrophages, we obtain tumour elimination in the presence of a type-I immune response (i.e., more Th1 and M1 cells, compared to the Th2 and M2 cells), or in the presence of a type-II immune response (i.e., more Th2 and M2 cells). Moreover, tumour elimination is also possible in the presence of a mixed type-I/type-II immune response. Tumour growth always occurs in the presence of a type-II immune response, as observed experimentally. Finally, tumour dormancy is the result of a delicate balance between the pro-tumour effects of M2 cells and the anti-tumour effects of M1 and Th1 cells.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B16 melanoma; M1 and M2 macrophages; Mathematical approach; Th1 and Th2 immune cells

Mesh:

Year:  2017        PMID: 28219660     DOI: 10.1016/j.jtbi.2017.02.022

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  5 in total

1.  Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies.

Authors:  R Eftimie; G Eftimie
Journal:  Acta Biotheor       Date:  2019-08-13       Impact factor: 1.774

Review 2.  Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.

Authors:  Vijayalakshmi Chelliah; Georgia Lazarou; Sumit Bhatnagar; John P Gibbs; Marjoleen Nijsen; Avijit Ray; Brian Stoll; R Adam Thompson; Abhishek Gulati; Serguei Soukharev; Akihiro Yamada; Jared Weddell; Hiroyuki Sayama; Masayo Oishi; Sabine Wittemer-Rump; Chirag Patel; Christoph Niederalt; Rolf Burghaus; Christian Scheerans; Jörg Lippert; Senthil Kabilan; Irina Kareva; Natalya Belousova; Alex Rolfe; Anup Zutshi; Marylore Chenel; Filippo Venezia; Sylvain Fouliard; Heike Oberwittler; Alix Scholer-Dahirel; Helene Lelievre; Dean Bottino; Sabrina C Collins; Hoa Q Nguyen; Haiqing Wang; Tomoki Yoneyama; Andy Z X Zhu; Piet H van der Graaf; Andrzej M Kierzek
Journal:  Clin Pharmacol Ther       Date:  2020-08-14       Impact factor: 6.875

3.  A size and space structured model of tumor growth describes a key role for protumor immune cells in breaking equilibrium states in tumorigenesis.

Authors:  Kevin Atsou; Fabienne Anjuère; Véronique M Braud; Thierry Goudon
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

Review 4.  Computational models of melanoma.

Authors:  Marco Albrecht; Philippe Lucarelli; Dagmar Kulms; Thomas Sauter
Journal:  Theor Biol Med Model       Date:  2020-05-14       Impact factor: 2.432

Review 5.  Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.

Authors:  Fabienne Maibach; Hassan Sadozai; S Morteza Seyed Jafari; Robert E Hunger; Mirjam Schenk
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.